Related Experiment Video

Updated: Dec 15, 2025

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.7K

Alterations in Serum-Free Amino Acid Profiles in Childhood Asthma

Joanna Matysiak1, Agnieszka Klupczynska2, Kacper Packi2

  • 1Faculty of Health Sciences, The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz, 62-800 Kalisz, Poland.

International Journal of Environmental Research and Public Health
|July 8, 2020
PubMed

Insights

Researchers identified specific amino acids (AAs) as potential biomarkers for childhood asthma. Altered levels of taurine, L-valine, and others may aid in early diagnosis and personalized treatment strategies for pediatric asthma.

Area of Science:

  • Biochemistry
  • Pediatric Pulmonology
  • Metabolomics

Background:

  • Childhood asthma diagnosis is challenging, relying on clinical signs and response to treatment.
  • Novel biomarkers are crucial for differentiating asthma phenotypes and personalizing therapy.
  • Amino acids (AAs) are fundamental metabolites with potential roles in disease pathogenesis.

Purpose of the Study:

  • To identify metabolomic-based biomarkers for childhood asthma among serum-free amino acids.
  • To investigate the role of proteinogenic and non-proteinogenic AAs in pediatric asthma.
  • To explore potential diagnostic markers for early asthma detection.

Main Methods:

  • Analysis of a wide panel of serum-free amino acids in asthmatic children and healthy controls.
  • Utilized high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) for AA quantification.
  • Employed uni- and multivariate statistical analyses to interpret the metabolomic data.

Main Results:

  • Asthmatic children showed decreased serum concentrations of taurine, L-valine, and DL-β-aminoisobutyric acid.
  • Elevated levels of ƴ-amino-n-butyric acid and L-arginine were observed in asthmatic children.
  • These specific AA alterations suggest a role in the pathogenesis of childhood asthma.

Conclusions:

  • Specific serum amino acid profiles may serve as novel biomarkers for childhood asthma.
  • Findings contribute to the understanding of asthma pathogenesis and personalized medicine.
  • Potential for integrating these biomarkers into clinical practice for improved diagnosis and treatment.

Keywords:
amino acidsasthmabiomarkerschildrendiagnosismetabolitesmetabolomics

More Related Videos

Murine Model of Allergen Induced Asthma08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.0K
A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

10.3K

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
3.2K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
619
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K